Harvard Bioscience (HBIO) - הון עצמי של החברה

Harvard Bioscience (HBIO) generates revenue by supplying laboratory equipment for electrophysiology and biosystem monitoring within the B2B sector. Manufacturing capacities in Europe and the US ensure stable demand from the academic community and the pharmaceutical industry. This chart illustrates the current share price, reaching 0.01, which accompanies a strategy to expand the product range by implementing automated cellular structure analysis systems to increase contract profitability.

The high macro-resilience of Harvard Bioscience (HBIO), supported by stable government grants in the laboratory equipment sector, ensures predictable asset dynamics. Calculating this metric by subtracting all liabilities from total assets determines the net equity value, allowing for a real-time assessment of the fundamental investment protection and the issuer's level of financial security through the current volume of balance sheet capital.